The purpose of this study is to measure how the quality of life, the structure of eye, and vision change after treatment for the opacities in the gel (vitreous) that fills the center of eye which cause vision disturbances commonly called "floaters".
In this study the vitreous floaters are treated using a Neodymium-doped yttrium-aluminum-garnet (Nd:YAG) laser. The FDA has approved the use of this laser to treat membranes in the eye.
Who can participate
Age range
18 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* Only one eye per patient will be included in this study
* Able and willing to give informed consent
* Age ≥18 years
* Suffering from symptomatic vitreous floaters
* Floaters arising from either/both:
* myopic vitreopathy
* posterior vitreous detachment
* Floaters meeting the following characteristics:
* Present for ≥3 months
* One single or more dense and well-defined vitreous opacities,
* A Weiss Ring or opacities which are within the safety area, at least 3mm away from the retina and 6mm away from the lens
* Visible on contact lens biomicroscopy
Exclusion Criteria:
* Patient presenting with vitreous opacities outside of the described safety area (within 3mm of the retina or 6mm from the lens)
* Have clinically significant cataract (lens opacification) in one or both eyes which are in the opinion of the examining doctor more significant in impacting vision as compared to that caused by vitreous opacities; or cataract expected to need cataract surgery during the duration of the study
* Present with untreated retinal tears or retinal holes requiring treatment at the discretion of the study investigator
* Have high risk of peripheral lesions requiring treatment at the discretion of the study investigator
* Have synchysis scintillans (unusual vitreous opacities from old blood)
* Have asteroid hyalosis (unusual vitreous opacities from cholesterol)
* Have vitreous hemorrhage (fresh blood in the center of the eye)
* Have active photopsia (flas…
Questions worth asking your doctor
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
Questions for the trial coordinator
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
What they're measuring
1
Measures of vitreous structure by quantitative ultrasonography